Brief: Lilly Q3 Adjusted EPS USD 7.48 Vs. IBES Estimate USD 6.49
BRIEF-Lilly Q3 Adjusted EPS USD 7.48 Vs. IBES Estimate USD 6.49 Oct 29 (Reuters) - Lilly Q3 revenue USD 24,397 million vs. IBES estimate USD 22,610 million.
- Q3 EPS USD 7.22
- Q3 Mounjaro revenue USD 10,723 million
- Q3 Zepbound revenue USD 5,352 million
Recent news on Eli Lilly and
See all newsUS stocks weekly: Spooky
Street View: Next-generation drugs bolster Lilly's growth outlook
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street slides as Alphabet revenue miss revives AI capex jitters